Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01931644 · ClinicalTrials.gov registry record
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
A clinical trial, sponsored by Sanguine Biosciences.
- Completed
- Registry status
- 17,667
- Enrollment target
NCT01931644 is a clinical trial that has completed, run by Sanguine Biosciences. The registered enrollment target is 17,667 participants.
The verdict
NCT01931644 has completed, sponsored by Sanguine Biosciences.
- COMPLETED
- Registry status
- 17,667 participants
- Enrollment target
Study Summary
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research. We make it easy for patients to contribute to research for medical conditions that matter most to them, regardless of their location or ability to travel.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17,667 participants |
| Start Date | 2013-07 |
| Est. Completion | 2024-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01931644
The ClinicalTrials.gov registry entry for NCT01931644 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 17,667 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanguine Biosciences, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01931644 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01931644 about?
NCT01931644 is a clinical study titled "At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions". We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research. We make it easy for patients to contribute to research for medical conditions that matter most to them, regardless of their location...
What is the current status of trial NCT01931644?
This trial is currently completed. The enrollment target is 17,667 participants. The study started on 2013-07. Estimated completion is 2024-04.
Who is sponsoring clinical trial NCT01931644?
This trial is sponsored by Sanguine Biosciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.